Solomon Adelaida, Negrea Mihai Octavian, Cipăian Călin Remus, Boicean Adrian, Mihaila Romeo, Rezi Cristina, Cristinescu Bianca Andreea, Berghea-Neamtu Cristian Stefan, Popa Mirela Livia, Teodoru Minodora, Stoia Oana, Neamtu Bogdan
Faculty of Medicine, "Lucian Blaga" University, 550024 Sibiu, Romania.
County Clinical Emergency Hospital of Sibiu, 550245 Sibiu, Romania.
Healthcare (Basel). 2023 Oct 9;11(19):2696. doi: 10.3390/healthcare11192696.
Metabolic-associated steatotic liver disease (MASLD), previously termed non-alcoholic fatty liver disease (NAFLD), has emerged as a prominent global cause of chronic liver disease and is increasingly recognized as associated with atherosclerotic vascular illness, consolidating its position along traditional cardiovascular risk factors. Individuals with MASLD exhibit a combination of metabolic syndrome risk factors, carotid atherosclerosis, and increased arterial stiffness, hinting at shared pathogenesis. In this study, we aim to explore liver involvement and arterial stiffness within metabolic syndrome. We enrolled 75 patients (30 male and 45 female) with either liver steatosis on conventional ultrasound, altered liver function tests, or the presence of cardiometabolic risk factors after excluding liver pathology other than MASLD. Clinical evaluation, laboratory measurements, abdominal and carotid ultrasounds, vibration-controlled transient elastography (VCTE, Fibroscan), and assessment with the Arteriograph (Tensiomed) were performed. The 26 patients diagnosed with MetS had significantly higher liver involvement as quantified via the hepatic steatosis index (HSI), Fibrosis-4 (FIB4), aspartate aminotransferase to platelet ratio index (APRI) category, and VCTE measurements, as well as Agile 3+ and Agile 4 scores which use a combination of clinical and laboratory parameters together with results obtained from VCTE to reflect the probability of advanced liver fibrosis or cirrhosis. Patients with MetS also exhibited more pronounced vascular involvement as quantified via arterial stiffness measurements and CIMT (carotid intima-media thickness). We applied a two-step clustering algorithm to enhance our analysis, which gave us pertinent insight into the interplay between metabolic syndrome elements and typologies of hepatic steatosis and arterial stiffness degrees. Notably, of the three obtained clusters, the cluster showing increased levels of hepatic steatosis and arterial stiffness also exhibited the highest prevalence of metabolic syndrome and its constituting components. The results have significant clinical implications, advocating for a comprehensive diagnostic approach when MetS or MASLD is suspected.
代谢相关脂肪性肝病(MASLD),以前称为非酒精性脂肪性肝病(NAFLD),已成为全球慢性肝病的一个主要病因,并越来越被认为与动脉粥样硬化性血管疾病有关,巩固了其在传统心血管危险因素中的地位。患有MASLD的个体表现出代谢综合征危险因素、颈动脉粥样硬化和动脉僵硬度增加的综合症状,这暗示了共同的发病机制。在本研究中,我们旨在探讨代谢综合征中的肝脏受累情况和动脉僵硬度。我们招募了75名患者(30名男性和45名女性),这些患者在排除MASLD以外的肝脏病变后,经传统超声检查发现有肝脂肪变性、肝功能检查异常或存在心脏代谢危险因素。进行了临床评估、实验室测量、腹部和颈动脉超声检查、振动控制瞬时弹性成像(VCTE,Fibroscan)以及使用动脉造影仪(Tensiomed)进行评估。经诊断患有代谢综合征的26名患者,通过肝脂肪变性指数(HSI)、Fibrosis-4(FIB4)、天冬氨酸转氨酶与血小板比值指数(APRI)类别以及VCTE测量,以及使用临床和实验室参数组合以及VCTE结果来反映晚期肝纤维化或肝硬化可能性的Agile 3+和Agile 4评分,量化显示出更高的肝脏受累程度。经代谢综合征诊断的患者,通过动脉僵硬度测量和颈动脉内膜中层厚度(CIMT)量化,也表现出更明显的血管受累情况。我们应用了两步聚类算法来加强分析,这使我们对代谢综合征要素与肝脂肪变性类型和动脉僵硬度程度之间的相互作用有了相关见解。值得注意的是,在获得的三个聚类中,显示肝脂肪变性和动脉僵硬度水平升高的聚类也表现出代谢综合征及其构成成分的最高患病率。这些结果具有重要的临床意义,提倡在怀疑患有代谢综合征或MASLD时采用综合诊断方法。